<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149524</url>
  </required_header>
  <id_info>
    <org_study_id>SB3-G31-BC</org_study_id>
    <secondary_id>2013-004172-35</secondary_id>
    <nct_id>NCT02149524</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer</brief_title>
  <official_title>A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB3 (Proposed Trastuzumab Biosimilar) and Herceptin® in Women With Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the
      Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab
      biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally
      Advanced Breast Cancer in Neoadjuvant Setting
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Pathological Complete Response (tpCR) Rate</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Clinical Response Rate (ORR)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>1 month after last dose of investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 month after the last administration of investigational product</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">875</enrollment>
  <condition>HER2 Positive Early or Locally Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB3 (proposed trastuzumab biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin (trastuzuamb)</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB3 (proposed trastuzumab biosimilar)</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>SB3 (proposed trastuzumab biosimilar)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged 18-65 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Non-metastatic, unilateral newly diagnosed primary breast cancer of clinical stage II
             to III including inflammatory breast cancer with:

               1. tumour size ≥ 2 cm

               2. histologically confirmed primary invasive carcinoma of the breast

               3. HER2-positivity confirmed by a central laboratory or an accredited local
                  laboratory and defined as immunohistochemistry (IHC) 3+ or fluorescence in situ
                  hybridisation (FISH)+

          -  Known hormone receptor (oestrogen receptor and progesterone receptor) status

          -  Baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography
             or multiple gated acquisition (MUGA) scan

          -  Subjects must be able to provide informed consent, which must be obtained prior to any
             study related procedures

        Exclusion Criteria:

          -  Metastatic (stage IV) or bilateral or multifocal/multicentric breast cancer

          -  History of any prior invasive breast carcinoma, except for subjects with a past
             history of ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS)
             treated with surgery only

          -  Past or current history of malignant neoplasms within 5 years prior to Randomisation,
             except for curatively treated carcinoma in situ of uterine cervix, basal cell
             carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms
             occurring more than 5 years prior to Randomisation are permitted if curatively treated
             with surgery only)

          -  Previous history of radiation therapy, immunotherapy, chemotherapy or biotherapy
             (including prior HER2 directed therapy) Major surgery within 4 weeks prior to
             Randomisation and minor surgery within 2 weeks prior to Randomisation (major surgery
             is defined as surgery which requires general anaesthesia)

          -  Serious cardiac illness that would preclude the use of trastuzumab such as:

               1. history of documented congestive heart failure (CHF) (New York Heart Association,
                  NYHA, class II or greater heart disease)

               2. LVEF &lt; 55% by echocardiography or MUGA scan

               3. angina pectoris requiring anti-anginal medication

               4. evidence of transmural infarction on electrocardiogram (ECG)

               5. uncontrolled hypertension (systolic &gt; 180 mmHg and/or diastolic &gt; 100 mmHg)

               6. clinically significant valvular heart disease

               7. high risk uncontrolled arrhythmias

          -  Serious pulmonary illness enough to cause dyspnoea at rest or requiring supplementary
             oxygen therapy

          -  Known history of hepatitis B virus (HBV), hepatitis C virus (HCV) or human
             immunodeficiency virus (HIV) infection

          -  Other concurrent serious illnesses that may interfere with planned therapy including
             severe cardiovascular, pulmonary, metabolic or infectious conditions

          -  Known hypersensitivity to the investigational product (IPs), non-IPs or any of the
             ingredients or excipients of the IPs or non-IPs

          -  Known hypersensitivity to murine proteins

          -  Known history of dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Pre-existing peripheral sensory or motor neuropathy ≥ grade 2, defined by National
             Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0

          -  Pregnant or lactating women. A pregnancy test result is required for all women of
             childbearing potential including women who had menopause onset within 2 years prior to
             Randomisation. Women of childbearing potential must agree to use contraceptive methods
             (see section 7.4.2) during the study and 6 months after the last dose of IP

          -  Concurrent hormonal therapy including birth control pills, ovarian hormone replacement
             for menopause, selective oestrogen receptor modulator (SERM) either for osteoporosis
             or breast cancer prevention

          -  Subjects unwilling to follow the study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Pivot</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon Hopital Jean Minjoz Service d'Oncologie Medicale</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>March 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2018</results_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 Positive Breast Cancer</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Biosimilar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Herceptin (Trastuzumab)</title>
          <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
        </group>
        <group group_id="P2">
          <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
          <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="438"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Herceptin (Trastuzumab)</title>
          <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
        </group>
        <group group_id="B2">
          <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
          <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="438"/>
            <count group_id="B2" value="437"/>
            <count group_id="B3" value="875"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Age data for one subject is missing.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="437"/>
                    <count group_id="B2" value="437"/>
                    <count group_id="B3" value="874"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="9.38"/>
                    <measurement group_id="B2" value="49.5" spread="9.51"/>
                    <measurement group_id="B3" value="49.6" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="438"/>
                    <count group_id="B2" value="437"/>
                    <count group_id="B3" value="875"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="438"/>
                    <measurement group_id="B2" value="437"/>
                    <measurement group_id="B3" value="875"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour</title>
        <time_frame>Week 24</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin (Trastuzumab)</title>
            <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
          </group>
          <group group_id="O2">
            <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
            <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour</title>
          <population>Per-protocol set</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pathological Complete Response (tpCR) Rate</title>
        <time_frame>Week 24</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin (Trastuzumab)</title>
            <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
          </group>
          <group group_id="O2">
            <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
            <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pathological Complete Response (tpCR) Rate</title>
          <population>Per-protocol set</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Clinical Response Rate (ORR)</title>
        <time_frame>Week 24</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin (Trastuzumab)</title>
            <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
          </group>
          <group group_id="O2">
            <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
            <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Clinical Response Rate (ORR)</title>
          <population>Per-protocol set</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS)</title>
        <time_frame>1 month after last dose of investigational product</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin (Trastuzumab)</title>
            <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
          </group>
          <group group_id="O2">
            <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
            <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS)</title>
          <population>Per-protocol set</population>
          <units>percentage of subjects without event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>1 month after the last administration of investigational product</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin (Trastuzumab)</title>
            <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
          </group>
          <group group_id="O2">
            <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
            <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <population>Per-protocol set</population>
          <units>percentage of subjects alive</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Herceptin (Trastuzumab)</title>
          <description>Intravenous administration
Herceptin (trastuzuamb): Intravenous administration</description>
        </group>
        <group group_id="E2">
          <title>SB3 (Proposed Trastuzumab Biosimilar)</title>
          <description>Intravenous administration
SB3 (proposed trastuzumab biosimilar): Intravenous administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Intraspinal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="420" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="426" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="634" subjects_affected="280" subjects_at_risk="438"/>
                <counts group_id="E2" events="654" subjects_affected="293" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="237" subjects_affected="113" subjects_at_risk="438"/>
                <counts group_id="E2" events="259" subjects_affected="125" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="198" subjects_affected="95" subjects_at_risk="438"/>
                <counts group_id="E2" events="180" subjects_affected="96" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="388" subjects_affected="135" subjects_at_risk="438"/>
                <counts group_id="E2" events="362" subjects_affected="143" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="90" subjects_affected="65" subjects_at_risk="438"/>
                <counts group_id="E2" events="143" subjects_affected="91" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="87" subjects_affected="50" subjects_at_risk="438"/>
                <counts group_id="E2" events="110" subjects_affected="61" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="88" subjects_affected="51" subjects_at_risk="438"/>
                <counts group_id="E2" events="107" subjects_affected="61" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="438"/>
                <counts group_id="E2" events="39" subjects_affected="26" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="182" subjects_affected="79" subjects_at_risk="438"/>
                <counts group_id="E2" events="186" subjects_affected="88" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="162" subjects_affected="55" subjects_at_risk="438"/>
                <counts group_id="E2" events="145" subjects_affected="57" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="37" subjects_at_risk="438"/>
                <counts group_id="E2" events="50" subjects_affected="39" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="438"/>
                <counts group_id="E2" events="27" subjects_affected="18" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="64" subjects_affected="40" subjects_at_risk="438"/>
                <counts group_id="E2" events="66" subjects_affected="44" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="47" subjects_affected="38" subjects_at_risk="438"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="54" subjects_affected="53" subjects_at_risk="438"/>
                <counts group_id="E2" events="41" subjects_affected="39" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="62" subjects_affected="42" subjects_at_risk="438"/>
                <counts group_id="E2" events="53" subjects_affected="37" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="150" subjects_affected="83" subjects_at_risk="438"/>
                <counts group_id="E2" events="150" subjects_affected="84" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="110" subjects_affected="63" subjects_at_risk="438"/>
                <counts group_id="E2" events="102" subjects_affected="68" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="162" subjects_affected="53" subjects_at_risk="438"/>
                <counts group_id="E2" events="124" subjects_affected="53" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="71" subjects_affected="32" subjects_at_risk="438"/>
                <counts group_id="E2" events="69" subjects_affected="25" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="43" subjects_affected="29" subjects_at_risk="438"/>
                <counts group_id="E2" events="40" subjects_affected="22" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="103" subjects_affected="41" subjects_at_risk="438"/>
                <counts group_id="E2" events="78" subjects_affected="40" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="138" subjects_affected="66" subjects_at_risk="438"/>
                <counts group_id="E2" events="148" subjects_affected="63" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="47" subjects_at_risk="438"/>
                <counts group_id="E2" events="74" subjects_affected="48" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="438"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="24" subjects_at_risk="438"/>
                <counts group_id="E2" events="39" subjects_affected="23" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="51" subjects_affected="32" subjects_at_risk="438"/>
                <counts group_id="E2" events="55" subjects_affected="31" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="40" subjects_affected="23" subjects_at_risk="438"/>
                <counts group_id="E2" events="42" subjects_affected="30" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="22" subjects_at_risk="438"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="438"/>
                <counts group_id="E2" events="46" subjects_affected="41" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="438"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="324" subjects_affected="283" subjects_at_risk="438"/>
                <counts group_id="E2" events="349" subjects_affected="299" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="62" subjects_affected="45" subjects_at_risk="438"/>
                <counts group_id="E2" events="61" subjects_affected="47" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="438"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="30" subjects_at_risk="438"/>
                <counts group_id="E2" events="58" subjects_affected="32" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Samsung Bioepis Co., Ltd.</organization>
      <email>sbregistry@samsung.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

